title: Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein.
abstract: Lung resistance-related protein (LRP) overexpression in leukaemic blast cells from acute leukaemia patients and the effect of LRP or P-glycoprotein (P-gp) on the clinical outcome of acute leukaemia were investigated individually by dividing patients into four groups. The complete remission rate of group I (LRP and P-gp both negative) was 81.7%, group II (only LRP positive) 87.5%, group III (only P-gp positive) 87.1% and group IV (LRP and P-gp both positive) 40.0%. There were no statistical differences between group I and groups II or III, but a significant difference was observed between groups I, II or III and group IV. Median overall survival in group IV was significantly shorter (4.6 months) than in groups I, II or III, although no significant differences were observed between group I and groups II or III (18.9, 20.5 and 31.8 months). There was a tendency for disease-free survival in group III to be longer than that in groups I, II or IV. The reasons for these findings are discussed. Our present results indicate that the co-existence of LRP and P-gp strongly influenced the effectiveness of induction chemotherapy and long-term prognosis, whereas the isolated presence of LRP or P-gp did not.
authors.affiliation: Department of Medicine, St. Marianna Medical University, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tsuji
authors.forename: T
authors.initials: T
authors.lastname: Motoji
authors.forename: I
authors.initials: I
authors.lastname: Sugawara
authors.forename: H
authors.initials: H
authors.lastname: Shiozaki
authors.forename: Y H
authors.initials: YH
authors.lastname: Wang
authors.forename: S
authors.initials: S
authors.lastname: Motomura
authors.forename: M
authors.initials: M
authors.lastname: Okada
authors.forename: T
authors.initials: T
authors.lastname: Yasunami
authors.forename: F
authors.initials: F
authors.lastname: Sano
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: H
authors.initials: H
authors.lastname: Kawada
authors.forename: N
authors.initials: N
authors.lastname: Maseki
authors.forename: S
authors.initials: S
authors.lastname: Hoshino
authors.forename: M
authors.initials: M
authors.lastname: Ishida
authors.forename: H
authors.initials: H
authors.lastname: Mizoguchi
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000378:metabolism*; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000378:metabolism; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D000970:Antineoplastic Agents